Reuters
Canadian eye drug developer QLT Inc's synthetic retinoid program, an experimental treatment for some inherited eye diseases that can cause blindness, could be worth "hundreds of millions" of dollars, the company's chairman said.
Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.
OphthalmologyWeb wants to hear from you. Submit your case studies, clinical pearls, practice management tips, editorial, or other manuscripts.
Learn more about writing for us